FAZIA, Maria Luigia
 Distribuzione geografica
Continente #
NA - Nord America 932
EU - Europa 797
AS - Asia 445
SA - Sud America 28
AF - Africa 1
Totale 2.203
Nazione #
US - Stati Uniti d'America 926
UA - Ucraina 152
CN - Cina 145
SG - Singapore 126
SE - Svezia 121
IE - Irlanda 120
TR - Turchia 111
GB - Regno Unito 104
FR - Francia 92
IT - Italia 82
IN - India 51
DE - Germania 46
FI - Finlandia 33
BR - Brasile 26
RU - Federazione Russa 26
BE - Belgio 9
CZ - Repubblica Ceca 5
HK - Hong Kong 4
CA - Canada 3
NL - Olanda 3
ES - Italia 2
IL - Israele 2
IR - Iran 2
MX - Messico 2
BD - Bangladesh 1
CO - Colombia 1
CR - Costa Rica 1
IQ - Iraq 1
JP - Giappone 1
KE - Kenya 1
NO - Norvegia 1
PL - Polonia 1
PY - Paraguay 1
VN - Vietnam 1
Totale 2.203
Città #
Chandler 187
Jacksonville 150
Dublin 119
Singapore 95
Southend 70
Ashburn 56
Ann Arbor 54
Izmir 52
Princeton 50
The Dalles 38
Nanjing 36
New York 33
Chieti 32
Wilmington 29
Beijing 25
Cambridge 24
Altamura 21
Woodbridge 20
Dearborn 17
Santa Clara 17
Washington 16
Nanchang 15
Los Angeles 13
Boardman 10
Brussels 9
Tianjin 9
Kunming 7
Moscow 7
Auburn Hills 6
Grevenbroich 6
Hebei 5
Hefei 5
Shenyang 5
Augusta 4
Hangzhou 4
Helsinki 4
Hong Kong 4
Norwalk 4
Orange 4
Turku 4
Zhengzhou 4
Brno 3
Foggia 3
Hanover 3
Jiaxing 3
Jinan 3
Lanzhou 3
Milan 3
Munich 3
Pescara 3
Rio de Janeiro 3
San Mateo 3
Seattle 3
Changsha 2
Curitiba 2
Guangzhou 2
Harbin 2
Kocaeli 2
Monmouth Junction 2
Ningbo 2
Piracicaba 2
Rome 2
San Francisco 2
San Salvo 2
Taizhou 2
Toronto 2
Tortoreto 2
Apodaca 1
Ardabil 1
Asunción 1
Baghdad 1
Belo Horizonte 1
Binh Duong 1
Bogotá 1
Brooklyn 1
Buffalo 1
Chongqing 1
Fairfield 1
Heredia 1
Hortolândia 1
Houston 1
Huizhou 1
Imperatriz 1
Inveruno 1
Killorglin 1
Leawood 1
Marabá Municipality 1
Mexico City 1
Mogi Guaçu 1
Mumbai 1
Nairobi 1
Nanning 1
Nanyang 1
Nova Iguaçu 1
Nuremberg 1
Olomouc 1
Osasco 1
Paris 1
Pedreiras 1
Penne 1
Totale 1.367
Nome #
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. 123
Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. 122
OVEREXPRESSION OF TOLL LIKE RECEPTOR 4 AS A BASIS OF CYCLOOXYGENASE 2-DEPENDENT ATHEROSCLEROTIC PLAQUE INSTABILITY IN HUMANS. 110
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteases activity 109
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 104
Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. 104
A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke 102
Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. 101
Association between 5-lipoxygenase expression and plaque instability in humans. 97
Reduced TIA-1 expression in vulnerable atherosclerotic plaques as a basis of cyclooxygenase-2-dependent plaque instability in humans. 90
Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk. 90
Novel determinants of plaque instability. 90
High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis. 89
Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. 87
Relationship between reduced BCL-2 expression in circulating mononuclear cells and early nephropathy in type 1 diabetes. 86
Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. 83
COX-2 expression in atherosclerosis: the good, the bad or the ugly? 80
HuR protein as potential modulator of angiotensin II type 1 receptor expression in human atherosclerotic plaque. 79
Enhanced soluble CD40 Ligand is responsible for endothelial dysfunction and monocyte activation in patients with diabetes mellitus. Effect of improved metabolic control. 78
COX-2 and atherosclerosis. 72
Role of angiotensin II receptor blockers in atherosclerotic plaque stability. 71
Enhanced soluble CD40 ligand is responsible for endothelial dysfunction and monocyte activation in patients with diabetes mellitus. Effect of improved metabolic control 70
Fisiopatologia della placca aterosclerotica 68
Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control 65
New insights on the molecular mechanisms of type-1 angiotensin II receptor blockers and their contribution to atherosclerotic plaque stabilization 61
Totale 2.231
Categoria #
all - tutte 9.151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.151


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202053 0 0 0 0 0 0 0 0 0 0 48 5
2020/2021190 27 0 28 2 19 38 4 0 22 30 9 11
2021/2022128 5 1 2 33 11 2 6 7 8 9 15 29
2022/2023461 30 73 25 62 51 81 20 28 64 3 12 12
2023/2024235 12 6 26 2 21 98 45 4 3 4 1 13
2024/2025318 30 68 43 7 12 25 3 9 35 21 65 0
Totale 2.231